Can Eylea HD and Dupixent Profits Revive Regeneron Stock?

Regeneron (REGN) reported Q2 revenue growth, buoyed by robust Dupixent sales and a 29% surge in Eylea HD sales, which partially offset the ongoing decline of its flagship Eylea due to competitive pressures. However, the company faces significant regulatory setbacks, including delayed FDA approvals for key Eylea HD applications and a complete response letter for its oncology drug odronextamab, both stemming from manufacturing site inspection issues at Catalent Indiana. While its oncology portfolio shows promise with new approvals and Libtayo's 18% H1 sales growth, these manufacturing-related hurdles and mixed late-stage trial results for itepekimab highlight persistent challenges to Regeneron's growth trajectory and investor confidence.

Analysis

Regeneron's current financial narrative is one of significant transition, marked by successful revenue diversification efforts that are being partially offset by considerable regulatory and pipeline headwinds. The company's legacy blockbuster, Eylea, continues to see its sales erode under intense competitive pressure from Roche's Vabysmo and the looming threat of biosimilars. While the newer Eylea HD formulation is providing a crucial buffer, with U.S. sales surging 29% in the second quarter, its future growth is now constrained by significant regulatory delays. A single point of failure—an adverse FDA inspection at a Catalent manufacturing site—has pushed back target action dates for key Eylea HD applications to August 2025 and resulted in a complete response letter for the oncology drug odronextamab. These setbacks overshadow positive developments, including the strong performance of Dupixent, which continues to secure new label expansions, and the encouraging growth of the oncology portfolio. Libtayo sales grew 18% in the first half of 2025, and Lynozyfic recently gained approval for multiple myeloma. However, the mixed results from the late-stage itepekimab studies further underscore the inherent pipeline risks, leaving investors to weigh the demonstrated growth from Dupixent and oncology against critical manufacturing dependencies and clinical trial uncertainties.

Key Decisions for Investors

• Investors should closely monitor disclosures related to the resolution of FDA inspection issues at the Catalent Indiana facility, as this is a key bottleneck affecting both the Eylea HD and odronextamab approval timelines.
• It is crucial to track the market share dynamics between Eylea HD and Roche's Vabysmo, as the success of the HD formulation in offsetting the base Eylea's decline is fundamental to near-term revenue forecasts.
• Given the recent stock pressure from pipeline and regulatory news, investors should re-evaluate if the current valuation adequately discounts these heightened execution risks against the long-term growth potential from the Dupixent and broader oncology franchises.
• Pay close attention to sales figures for Dupixent and Libtayo in upcoming earnings reports, as their continued growth is the primary driver for diversifying the company's revenue base away from its challenged ophthalmology segment.